Postdoc – Van den Heuvel-Eibrink Group

The van den Heuvel-Eibrink Group is looking for an enthusiastic, highly motivated postdoctoral researcher with translational activities, that include identification of clinical and genetic risk factors for ototoxicity as well as implementation of recent research findings into clinical practice in children with cancer.

The van den Heuvel-Eibrink Group

The overall aim of our group is to 1) increase survival without toxicity in children with renal cancer, and 2) to identify early and late (genetic and clinical) side effects of childhood cancer treatment. The Van den Heuvel-Eibrink Group has been established in very first years of the Princess Máxima Center for Pediatric Oncology, the Dutch national hospital for childhood cancer. This institute has the ambition to cure every child with cancer, while providing optimal quality of life. Hereto, scientific research and clinical care are closely integrated, providing a unique opportunity for translational research. In our group, research includes epidemiological, biological and clinical-translational studies on renal tumors as well as studies on early and late genetic susceptibility, and clinical as well as impact, of endocrine, ototoxic and nephrotoxic side effects.  We collaborate closely with the departments of ENT, audiology, endocrinology, nephrology, radiotherapy and internal medicine and gynecology in the Wilhelmina Childrens Hospital and UMCU as well as internal medicine- endocrinology and complex genetics in the Erasmus MC, in Rotterdam, several other research groups, including wet labs, both within the Princess Máxima Center and (inter-)nationally (even globally). Core values in our group are collaboration, social involvement, scientific curiosity and clinical impact. As a postdoc, you will collaborate directly with the PI and (MD-)PhD students on a project which aims to find ground for implementing otoprotectives in children with cancer.

Research Project

In children with cancer cisplatin has been shown to be a promising successful agents, that, survival dramatically. One of the major components of this success is the use of the chemotherapeutic agent Cisplatin. Unfortunately,  however, in the past decade, we and others have shown, that 50% of our patients develops hearing loss, due to cisplatin.  Recently, an otoprotective drug has become available, that reduces this risk for hearing loss, tinnitus and vertigo substantially. Currently, our research focusses on identifying the patients that benefit most from this intervention, and to implement this otoprotective. The project will include supervision of an MD-PhD student, performing and supporting research on  identifying (clinical and genetic) risk factors, by existing data, as well as a cross sectional study, implementation of an otoprotective, as well as providing evidence by reviewing the literature, together with international colleagues.


  • PhD degree in health science/epidemiology
  • Proven affinity with, clinical/academic nursing research
  • Experience with R, next generation sequencing associated GWAS data analysis would be optimal
  • Interest in translational childhood cancer research
  • (Willingness to) obtain a BROK certificate
  • Team player, who enjoys working in and contributing to a multidisciplinary team
  • Creative mind, who is willing to provide input and contribute to the development of our research group
  • Representative and social skills, for networking in the group and beyond including in the international field
  • Excellent communication and presentation skills

Our job offer

We offer a challenging position in an international, multidisciplinary research environment, which combines clinical oncology, genomics and optimal Quality of life research. The position is based on 32 – 36 hours per week, initially for one year, with the intention to extend after this period. Your gross monthly salary will depend on experience and background, starting in scale 60 with 8,33% gross monthly salary holiday allowance and 8,33 % end-of-year bonus. The Princess Máxima Center operates according to the collective labor agreement ‘cao algemene ziekenhuizen’.

The Princess Máxima Center

The Princess Máxima Center for Pediatric Oncology is a research hospital concentrating healthcare, research and education with regard to cancer in children in a single location in Utrecht. The institute aims to provide the highest level of care for all children with cancer, with optimal quality of life. The center brings together the best possible care and scientific research, creating a unique interdisciplinary institute for pediatric oncology in Europe.


Are you our new colleague? We are looking forward to meeting you! You can apply directly by clicking on the orange button on this page. This vacancy will close on June 21st 2024. Potential candidates will be invited for interviews in the beginning of July. For more information about the vacancy, you are welcome to contact Prof. dr. Marry M. van den Heuvel-Eibrink.

Acquisitie naar aanleiding van deze vacature wordt niet op prijs gesteld.

Solliciteer direct

Een aantal andere vacatures in Research